Anttinen J, Kautiainen H, Kuopio T
Department of Pathology, Jyväskylä Central Hospital, Keskussairaalantie 19, 40620 Jyväskylä, Finland.
Br J Cancer. 2006 Jan 16;94(1):147-51. doi: 10.1038/sj.bjc.6602895.
We examined the effect of population-based screening programme on tumour characteristics by comparing carcinomas diagnosed during the prescreening (N=341) and screening (N=552) periods. We identified screen detected (N=224), interval (N=99) and clinical cancer (N=229) cases. Median tumour size and proportion of axillary lymph node negative cases were 1.5 cm and 65% in the screen detected group, 2.0 cm and 44% in cases found outside the screening, and 3.2 cm and 41% in the cases from the prescreening period. Survival of the breast cancer patients was 66% (95% CI, 60-71%) in the prescreening era group and 73% (95% CI, 66-78%) in the screening era group after 10 years of follow-up. In the screening era group the survival of the screen detected cases was 86% (95% CI, 80-90%) and that of the clinical cancer cases 73% (95% CI, 66-78%) after 10 years. In multivariate analysis the risk of breast cancer death was not significantly different between the prescreening and screening periods (HR 0.82; 95% CI 0.59-1.12, P=0.21). Detection by screening was not an independent prognostic factor in multivariate analysis (HR 0.75; CI 95% 0.50-1.12; P=0.17).
我们通过比较筛查前(N = 341)和筛查期间(N = 552)诊断出的癌症,研究了基于人群的筛查计划对肿瘤特征的影响。我们确定了筛查发现的病例(N = 224)、间隔期病例(N = 99)和临床癌症病例(N = 229)。筛查发现组的肿瘤大小中位数和腋窝淋巴结阴性病例比例分别为1.5 cm和65%,筛查外发现的病例为2.0 cm和44%,筛查前时期的病例为3.2 cm和41%。在随访10年后,筛查前时代组乳腺癌患者的生存率为66%(95%CI,60 - 71%),筛查时代组为73%(95%CI,66 - 78%)。在筛查时代组中,筛查发现病例10年后的生存率为86%(95%CI,80 - 90%),临床癌症病例为73%(95%CI,66 - 78%)。多因素分析显示,筛查前和筛查期间乳腺癌死亡风险无显著差异(HR 0.82;95%CI 0.59 - 1.12,P = 0.21)。在多因素分析中,筛查发现并非独立的预后因素(HR 0.75;CI 95% 0.50 - 1.12;P = 0.17)。